Trial Profile
A Phase 3, Double-Blind, Randomized, Factorial, Efficacy and Safety Study of Azilsartan Medoxomil Plus Chlortalidone Fixed-Dose Combination in Subjects With Moderate-to-Severe Hypertension.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Azilsartan medoxomil/chlortalidone (Primary) ; Azilsartan medoxomil; Chlortalidone
- Indications Essential hypertension
- Focus Biomarker; Pharmacogenomic; Registrational; Therapeutic Use
- 04 Dec 2012 Planned number of patients changed from 1650 to 1815.
- 20 Jun 2011 Results presented at the 21st European Meeting on Hypertension.
- 24 May 2011 Results presented at the 26th Annual Scientific Meeting of the American Society of Hypertension.